Recent News

• 10.16.2026 - Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
• 01.29.2025 - Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• 11.26.2024 - Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• 11.13.2024 - Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• 11.07.2024 - Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• 10.28.2024 - Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
• 10.24.2024 - Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
• 10.24.2024 - Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
• 08.29.2024 - Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Recent Filings

• 09.23.2026 - 144 Report of proposed sale of securities
• 09.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.22.2026 - 3 Initial statement of beneficial ownership of securities